Boardroom Alpha
Boardroom Alpha
BBBY · Current Report (Form 8-K) · Filed May 19, 2026

Bed Bath & Beyond Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 19, 2026
Period
May 14, 2026
Ticker
BBBY
Accession
0001130713-26-000043
Boardroom Alpha · Filing insights

Stockholders increased authorized common shares to 200M, approved charter and equity plan amendments, elected directors, and endorsed Say-on-Pay.

About Bed Bath & Beyond Inc
Market cap
$478M
1Y TSR
−17.0%
3Y TSR
−37.9%
Board grade
D
Sector
Consumer Cyclical
CEO
Marcus Lemonis
Last annual meeting: May 14, 2026 · View full Bed Bath & Beyond Inc profile →
bbby-20260514

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

MAY 14, 2026
Date of Report (date of earliest event reported)
Bed Bath & Beyond, Inc.
(Exact name of registrant as specified in its charter)
Delaware000-4185087-0634302
(State or other jurisdiction of(Commission File Number)(I.R.S. Employer
incorporation)Identification No.)

433 W. Ascension Way, 3rd Floor
Murray, Utah 84123
(Address of principal executive offices)
 
(801) 947-3100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareBBBYNew York Stock Exchange
Warrants to Purchase Shares of Common StockBBBY WSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported below under Item 5.07 of this Current Report on Form 8-K, on May 14, 2026, Bed Bath & Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “2026 Annual Meeting”), at which the Company’s stockholders, at the recommendation of the Board of Directors of the Company, approved an amendment and restatement of the Company’s Amended and Restated 2005 Equity Incentive Plan (the “Restated Plan”). The approval of the Restated Plan by stockholders approved an increase in the number of shares available for issuance under the Restated Plan by 4,291,000 newly authorized shares, plus shares that become available through the amended share recycling provisions. A further description of the Restated Plan is included in the section titled “Proposal 6 – Approval of an Amendment and Restatement of the Company’s Amended and Restated 2005 Equity Incentive Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (“SEC”) on March 27, 2026 (the “Definitive Proxy Statement”).

The foregoing description of the Restated Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Restated Plan, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Company’s 2026 Annual Meeting, the Company’s stockholders approved an amendment (the “Charter Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”). The Charter Amendment amends the Company’s Charter to increase the number of authorized shares of the Company’s common stock, par value $0.0001 per shares from 100,000,000 to 200,000,000 shares. A further description of the Charter Amendment is included in the section titled “Proposal Four – Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock” in the Company’s Definitive Proxy Statement.

On May 14, 2026, the Company filed a Certificate of Amendment containing the Charter Amendment (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective upon filing.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting was held on May 14, 2026. There were 69,342,333 shares of stock outstanding eligible to be voted at the Annual Meeting, of which 49,326,700 shares of stock were presented in person or represented by proxy at the Annual Meeting, which constituted a quorum to conduct business. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which are described in detail in the Definitive Proxy Statement.

Proposal 1 - Election of Directors

The election of the individuals named below as members of the Board of Directors, to serve for a term of one year ending at the 2027 annual meeting of stockholders and until such person’s respective successor has been duly elected and qualified or until such person’s earlier death, resignation, or removal, was approved by the following vote:

NameForWithheldBroker Non-Votes
Marcus A. Lemonis31,348,555825,44317,152,702
Joanna C. Burkey30,659,2981,514,70017,152,702
Barclay F. Corbus23,454,5678,719,43117,152,702
William B. Nettles, Jr.23,474,9438,699,05517,152,702
Debra G. Perelman29,851,8952,322,10317,152,702
Dr. Robert J. Shapiro24,207,5757,966,42317,152,702
Joseph J. Tabacco, Jr.24,350,4467,823,55217,152,702

2


Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The ratification of the Audit Committee’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved by the following vote:

ForAgainstAbstainBroker Non-Votes
41,252,7977,983,09490,8090

Proposal 3 – Say on Pay Vote

The approval, on an advisory (non-binding) basis, of the compensation paid by the Company to its named executive officers (the “Say on Pay Vote”), was approved by the following vote:

ForAgainstAbstainBroker Non-Votes
30,810,6231,185,181178,19417,152,702

Proposal 4 – Amendment to the Companys Amended and Restated Certificate of Incorporation

The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock was approved by the following vote:

ForAgainstAbstainBroker Non-Votes
45,515,6743,479,427331,5990

Proposal 5 – Adjournment of the Annual Meeting

The approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4 and/or Proposal 6 was approved by the following vote:

ForAgainstAbstainBroker Non-Votes
45,370,5333,833,448122,7190

Although Proposal 5 was approved, an adjournment of the Annual Meeting was not necessary because the Company’s stockholders approved Proposals 4 and 6.

Proposal 6 – Amendment and Restatement of the Company’s Amended and Restated 2005 Equity Incentive Plan

The approval of an amendment and restatement of the Company’s Amended and Restated 2005 Equity Incentive Plan was approved by the following vote:

ForAgainstAbstainBroker Non-Votes
29,266,4062,655,543252,04917,152,702

3




Item 9.01 Financial Statements and Exhibits


(d) Exhibits

Exhibit No.
Description of Exhibit
Certificate of Amendment to Amended and Restated Certificate of Incorporation
Amended and Restated Bed Bath & Beyond, Inc. 2005 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed by the Company with the SEC on March 11, 2026)
104
The XBRL tags on the cover page of this Form 8-K are embedded within the Inline XBRL document.


4


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BED BATH & BEYOND, INC.
By:
/s/ Melissa Smith
Melissa Smith
General Counsel and Corporate Secretary
Date:May 19, 2026



5
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Bed Bath & Beyond Inc (BBBY)

Reference

Frequently asked questions

When did Bed Bath & Beyond Inc file this 8-K?
Bed Bath & Beyond Inc (BBBY) filed this Current Report (Form 8-K) with the SEC on May 19, 2026. The accession number assigned by EDGAR is 0001130713-26-000043.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders increased authorized common shares to 200M, approved charter and equity plan amendments, elected directors, and endorsed Say-on-Pay. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Bed Bath & Beyond Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Bed Bath & Beyond Inc has filed under CIK 1130713, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer